Pharmaceuticals & Therapeutics

A groundbreaking NEJM report shows Neutrolis's therapy rapidly reversed severe Lupus symptoms, validating a new, non-immunosuppressive approach.

With a strategic investment from Persephoni, SelSym Biotech is advancing SymClot, a synthetic blood-clotting agent that could redefine emergency medicine.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

A key approval for a single raw material in Japan reveals the new frontier in biopharma: a global race for regulatory compliance that could fast-track cell therapies.

Seattle's Sound Pharma completes key Phase 3 enrollment for SPI-1005, putting the first-ever approved drug for debilitating Meniere's disease on the horizon.

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

Milla Pharmaceuticals' new FDA approval for a vital acidosis drug offers hope for hospitals battling chronic shortages and marks a key strategic win for parent A.forall.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

The biotech's complex warrant restructuring is more than a balance sheet clean-up; it's a strategic masterstroke paving the way for its MASH drug.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.